On his first earnings call, the new CEO said he wanted to make a quick decision on Kite, which will have its own CEO and autonomy. The unit's Yescarta posted 19% sequential revenue growth.
Saying he wanted to “make some swift decisions here,” new Gilead Sciences Inc. CEO Daniel O’Day told the company’s first quarter 2019 earnings call on 2 May that Kite Pharma Inc. will become a separate business unit of the company with its own CEO, for whom a search effort is under way.
O’Day joined Gilead from Roche and took over as CEO on 1 March, succeeding John Milligan, who along with predecessor...
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Nancy tests Jira ticket SPARC-1036: Make anchor link work on initial page load
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
